Tvardi Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 de nov. de 2025, TVRD reported earnings of -0.59 USD per share (EPS) for Q3 25, beating the estimate of -1.01 USD, resulting in a 42.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.95% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.65 USD, with revenue projected to reach -- USD, implying an aumentar of 10.17% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Tvardi Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Tvardi Therapeutics, Inc. Common Stock reported EPS of -$0.59, beating estimates by 42.14%, and revenue of $0.00, 0% as expectations.
How did the market react to Tvardi Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.95%, changed from $4.11 before the earnings release to $4.03 the day after.
When is Tvardi Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 09 de mar. de 2026.
What are the forecasts for Tvardi Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analistas, Tvardi Therapeutics, Inc. Common Stock is expected to report EPS of -$0.65 and revenue of -- for Q4 2025.